A carregar...
Targeting HER2(+) breast cancer: the TBK1/IKKε axis
HER2(+) breast cancer (BC) is a highly aggressive subtype, affecting ~20% of BC patients. Current treatments include adjuvant or neoadjuvant chemotherapy plus anti-HER2 agents such as trastuzumab, a monoclonal antibody directed against HER2. Despite improvement in disease free survival, most patient...
Na minha lista:
| Publicado no: | Oncoscience |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Impact Journals LLC
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4278282/ https://ncbi.nlm.nih.gov/pubmed/25594009 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|